Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Nivolumab in combination with CIMAvax-EGF for lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.01.19
Views: 961

Dr Grace Dy - Roswell Park Cancer Institute, USA

Dr Grace Dy talks to ecancer at II Congreso oncológico ecancer-Liga Colombiana contra el Cáncer 2018 in Bogotá, Colombia.

She discusses the highlights from a Phase I study using nivolumab in combination with CIMAvax-EGF, which demonstrated that the dosages were safe.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation